Twin Tree Management, LP Incyte Corp Call Options Transaction History

Twin Tree Management, LP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 13, 2024	BUY	$51.18 - $63.75 $81,888 - $102,000	1,600 New	1,600 $96,000
Q3 2021 Nov 12, 2021	SELL	$68.67 - $84.02 $501,291 - $613,346	-7,300 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$79.87 - $87.53 $71,883 - $78,777	900 Added 14.06%	7,300 $614,000
Q1 2021 May 17, 2021	SELL	$76.02 - $100.5 $1.33 Million - $1.76 Million	-17,500 Reduced 73.22%	6,400 $520,000
Q4 2018 Feb 13, 2019	BUY	$58.5 - $69.94 $725,400 - $867,256	12,400 Added 107.83%	23,900 $1.52 Million
Q3 2018 Nov 09, 2018	BUY	$61.75 - $74.23 $710,125 - $853,645	11,500 New	11,500 $794,000
Q1 2018 May 09, 2018	SELL	$83.06 - $100.98 $249,180 - $302,940	-3,000 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$93.56 - $116.6 $973,024 - $1.21 Million	-10,400 Reduced 77.61%	3,000 $284,000
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $1.46 Million - $1.85 Million	13,400	13,400 $1.56 Million

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

Stay updated on Twin Tree Management, LP with notifications on news.